[Mass spectrometry application for clinical diagnostics chairmen's introductory remarks]

Kuniaki Saito, Fumio Nomura

Research output: Contribution to journalReview article

Abstract

Mass spectrometry has been recently used in clinical diagnostics, especially drug screening, newborn screening, and bacterial identification; therefore, the current developments in mass spectrometry platforms (i. e. GC-MS, LC-MS/MS) and applications for clinical diagnosis will be discussed. Technological advances in drug analyses and bacterial identification using mass spectrometry during recent years have provided an effective tool for the clinical laboratory. This symposium provides a comprehensive future overview of the latest technologies to quantify metabolites, drugs, and identify bacterial proteins using mass spectrometry, proposed for potential new biomarker development.

Original languageEnglish
Pages (from-to)803-804
Number of pages2
JournalRinsho byori. The Japanese journal of clinical pathology
Volume61
Issue number9
Publication statusPublished - 01-09-2013
Externally publishedYes

Fingerprint

Mass Spectrometry
Preclinical Drug Evaluations
Bacterial Proteins
Pharmaceutical Preparations
Biomarkers
Technology

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{81527ce8ec0644dbaafc0daac3b9b733,
title = "[Mass spectrometry application for clinical diagnostics chairmen's introductory remarks]",
abstract = "Mass spectrometry has been recently used in clinical diagnostics, especially drug screening, newborn screening, and bacterial identification; therefore, the current developments in mass spectrometry platforms (i. e. GC-MS, LC-MS/MS) and applications for clinical diagnosis will be discussed. Technological advances in drug analyses and bacterial identification using mass spectrometry during recent years have provided an effective tool for the clinical laboratory. This symposium provides a comprehensive future overview of the latest technologies to quantify metabolites, drugs, and identify bacterial proteins using mass spectrometry, proposed for potential new biomarker development.",
author = "Kuniaki Saito and Fumio Nomura",
year = "2013",
month = "9",
day = "1",
language = "English",
volume = "61",
pages = "803--804",
journal = "Rinsho byori. The Japanese journal of clinical pathology",
issn = "0047-1860",
publisher = "Nihon Rinsho Byori Gakkai",
number = "9",

}

[Mass spectrometry application for clinical diagnostics chairmen's introductory remarks]. / Saito, Kuniaki; Nomura, Fumio.

In: Rinsho byori. The Japanese journal of clinical pathology, Vol. 61, No. 9, 01.09.2013, p. 803-804.

Research output: Contribution to journalReview article

TY - JOUR

T1 - [Mass spectrometry application for clinical diagnostics chairmen's introductory remarks]

AU - Saito, Kuniaki

AU - Nomura, Fumio

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Mass spectrometry has been recently used in clinical diagnostics, especially drug screening, newborn screening, and bacterial identification; therefore, the current developments in mass spectrometry platforms (i. e. GC-MS, LC-MS/MS) and applications for clinical diagnosis will be discussed. Technological advances in drug analyses and bacterial identification using mass spectrometry during recent years have provided an effective tool for the clinical laboratory. This symposium provides a comprehensive future overview of the latest technologies to quantify metabolites, drugs, and identify bacterial proteins using mass spectrometry, proposed for potential new biomarker development.

AB - Mass spectrometry has been recently used in clinical diagnostics, especially drug screening, newborn screening, and bacterial identification; therefore, the current developments in mass spectrometry platforms (i. e. GC-MS, LC-MS/MS) and applications for clinical diagnosis will be discussed. Technological advances in drug analyses and bacterial identification using mass spectrometry during recent years have provided an effective tool for the clinical laboratory. This symposium provides a comprehensive future overview of the latest technologies to quantify metabolites, drugs, and identify bacterial proteins using mass spectrometry, proposed for potential new biomarker development.

UR - http://www.scopus.com/inward/record.url?scp=84893115946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893115946&partnerID=8YFLogxK

M3 - Review article

VL - 61

SP - 803

EP - 804

JO - Rinsho byori. The Japanese journal of clinical pathology

JF - Rinsho byori. The Japanese journal of clinical pathology

SN - 0047-1860

IS - 9

ER -